Clinical Trials Sponsored by Cerenis Therapeutics, SA

Total 32 results

Cerenis Therapeutics, SA

Completed

Exploratory Study of Plaque Regression (EXPRESS)

Heterozygous Familial Hypercholesterolemia

Canada
Cerenis Therapeutics, SA

Terminated

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases (TANGO)

Familial Hypoalphalipoproteinemia

France, United States, Belgium, Canada, Israel, Italy, Netherlands
Cerenis Therapeutics, SA

Completed

Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)

Homozygous Familial Hypercholesterolemia

United States, Canada, Italy, Netherlands, United Kingdom
Cerenis Therapeutics, SA

Completed

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial (CHI SQUARE)

Acute Coronary Syndrome

Canada, United States, France, Netherlands
Cerenis Therapeutics, SA
South Australian Health and Medical Research Institute

Completed

CER-001 Atherosclerosis Regression ACS Trial (CARAT)

Acute Coronary Syndromes

United States, Australia, Netherlands, Hungary
Ryvu Therapeutics SA

Not yet recruiting

RVU120 Rollover Study (ROVER-01)

Advanced Solid Tumors | High-risk Myelodysplastic Syndrome | Acute Myeloid Leukaemia (AML)

Poland, Spain
Ryvu Therapeutics SA

Active, not recruiting

RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors

Advanced Solid Tumor

Spain, Poland
SeneXta Therapeutics SA

Completed

Safety and Pharmacokinetics of SNX-001 in Healthy Aged Volunteers

Safety

Germany
Ryvu Therapeutics SA

Recruiting

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Myelofibrosis

Italy, Poland
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML (RIVER-81)

Acute Myeloid Leukemia

Spain, France, Italy, Poland
Ryvu Therapeutics SA

Active, not recruiting

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | High-risk Myelodysplastic Syndrome

United States, Poland
Ryvu Therapeutics SA

Active, not recruiting

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (RIVER-52)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome

Spain, Poland, Italy, France
Domain Therapeutics SA

Active, not recruiting

DT-9081 Study in Participants with Advanced, Recurrent or Metastatic Solid Tumours (EPRAD)

Solid Tumor, Adult

France, Belgium
Calliditas Therapeutics Suisse SA

Active, not recruiting

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Squamous Cell Carcinoma of Head and Neck

Spain, France, United States, Germany, Italy, Poland, United Kingdom
Calliditas Therapeutics Suisse SA

Completed

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM)

Primary Biliary Cholangitis | Liver Stiffness

United States, Spain, France, Australia, Israel, Canada, Switzerland, Italy, New Zealand, Germany, Poland, Greece, United Kingdom, Belgium, Austria, Czechia, Hungary, Sweden
Ceres Brain Therapeutics
Eurofins Optimed

Recruiting

Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects (CBT101)

Neurologic Diseases, General

France
Ryvu Therapeutics SA
Menarini Group

Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) (JASPIS-01)

Non-Hodgkin Lymphoma, B-cell

Spain, Poland, France
iTeos Belgium SA

Recruiting

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Metastatic NSCLC - Non-Small Cell Lung Cancer | Locally Advanced NSCLC - Non-Small Cell Lung Cancer

United Kingdom, Spain, Belgium, France, United States, Switzerland, Italy, Germany, Canada, Czechia, Poland
Repare Therapeutics
Debiopharm International SA

Recruiting

Study of RP-6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC)

Advanced Solid Tumor

United States, Canada, Denmark, United Kingdom
iTeos Belgium SA

Completed

First-In-Human Study of EOS884448 in Participants With Advanced Cancers.

Advanced Cancer

Belgium
iTeos Belgium SA

Active, not recruiting

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

Selected Advanced Solid Tumors

United States, Belgium
Domain Therapeutics Australia Pty Ltd
Domain Therapeutics SA

Recruiting

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (DOMISOL)

Advanced Solid Tumors

Australia
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF302)

Upper Tract Urothelial Carcinomas | Urothelial Bladder Cancer

United States, France, Canada, Spain, Italy, Belgium, Germany, Netherlands, United Kingdom, Bulgaria, Greece
iTeos Belgium SA
GlaxoSmithKline; iTeos Therapeutics

Active, not recruiting

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006)

Melanoma | Head and Neck Cancer | Lung Cancer | Advanced Cancer

France, Spain, Belgium, United States, United Kingdom, Italy
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

Korea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

United States, Belgium, Germany, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
Rhizen Pharmaceuticals SA
Incozen Therapeutics Pvt Ltd

Recruiting

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer (TNBC)

India
Rhizen Pharmaceuticals SA
Incozen Therapeutics Pvt Ltd

Completed

Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.

SARS-CoV-2 Infection

India
iTeos Therapeutics
Bristol-Myers Squibb; GlaxoSmithKline; iTeos Belgium SA

Terminated

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, France, Spain, Belgium
iTeos Therapeutics
Merck Sharp & Dohme LLC; iTeos Belgium SA

Completed

First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer (IO-001)

Solid Tumor, Adult

Spain, United States, France, Korea, Republic of, Belgium, United Kingdom
Xuanwu Hospital, Beijing
H. Lundbeck A/S; Hoffmann-La Roche; Genentech, Inc.; Life Molecular Imaging SA; APRINOIA... and other collaborators

Recruiting

A Direct Comparative Study of Tau Tracer in Patients With Alzheimer's Disease (HTH)

Alzheimer Disease

China
GCP-Service International West GmbH
Saint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaborators

Active, not recruiting

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms ((MDS))

Low Risk Myelodysplastic Syndromes

Spain, Poland, Italy, Germany, France

Clinical Trials Sponsored by Cerenis Therapeutics, SA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations